# Progress Note 07 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN
- Date: 2026-10-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Periodic adult preventive visit, on day 10 of the first cycle of chemotherapy after surgery. **S**

## History of present illness

Ms. Hansberry, now 33, comes for her yearly preventive visit on day 10 of the first cycle of fluorouracil, leucovorin and irinotecan after her pancreaticoduodenectomy. The cycle went well: one day of nausea settled with olanzapine, two loose stools on day 4 controlled with loperamide, and no fever. She takes pancrelipase three capsules with meals and two with snacks, and her stools are formed. Insulin glargine is 10 units at night; fasting readings are 110 to 140 mg/dL with no low readings. She takes apixaban twice a day without bleeding. The tingling in her fingers in the cold is fading now that oxaliplatin has stopped. She writes most mornings and has finished a draft of the new play's second act. Her PHQ-9 today is 5. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 33 |
| Active conditions | Pancreatic adenocarcinoma after six cycles of modified FOLFIRINOX and pancreaticoduodenectomy (R0); on chemotherapy after surgery; diabetes due to pancreatic disease on insulin; exocrine pancreatic insufficiency on pancrelipase |
| Medicines | Fluorouracil, leucovorin and irinotecan every two weeks; pegfilgrastim; apixaban 2.5 mg twice daily; insulin glargine 10 units; pancrelipase; pantoprazole; olanzapine, ondansetron and loperamide as needed; oxycodone rarely |
| Mood | PHQ-9 5 |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchetti-Fields. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than before surgery |
| Psychosocial | Close friends and fellow writers visit and drive her to treatment; worry about the cancer returning; writing gives her purpose |
| Tobacco | Never smoked |
| Alcohol and drugs | No alcohol since diagnosis; no drugs |
| Physical activity | Walks 20 minutes by the river most days |
| Nutrition | Five small meals a day with pancrelipase; weight steady since surgery; follows the dietitian's plan |
| Sleep | Seven hours, broken on the nights after chemotherapy |
| Sexual and reproductive health | Not sexually active now; would use condoms and talk to the clinic first; does not want a pregnancy during or soon after treatment |
| Safety at home | Feels safe; no one hurts, threatens, or controls her; no firearm in the home |
| Road safety | Wears a seat belt; friends drive her on treatment days |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for two days after each cycle; no fever, night sweats or weight loss since surgery |
| Eyes | Negative | No vision change; dilated eye examination last week normal |
| Ears, nose, mouth, and throat | Negative | No mouth sores |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Nausea for one day and two loose stools after the cycle; stools otherwise formed; no abdominal pain or yellow eyes |
| Genitourinary | Negative | No urinary symptoms; periods irregular since chemotherapy |
| Breast | Negative | No lump or nipple discharge |
| Musculoskeletal | Negative | No joint or bone pain |
| Integumentary | Negative | Hair thinning; incision healed |
| Neurological | Positive | Tingling in the fingertips in the cold, fading |
| Endocrine | Negative | No low glucose readings |
| Hematologic and lymphatic | Negative | No bruising or bleeding on apixaban |
| Psychiatric | Negative | Mood fair; PHQ-9 5; no thoughts of self-harm |

14 systems reviewed. **S**

## Current medications

- Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast **S**
- Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle **S**
- Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed **S**
- Insulin glargine 100 units/mL pen, 10 units under the skin at night **S**
- Pancrelipase delayed-release capsule (lipase 36,000 units), three capsules with each meal and two with each snack **S**
- Irinotecan 20 mg/mL injection, 184 mg (120 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery **S**
- Leucovorin 10 mg/mL injection, 612 mg (400 mg/m2) intravenously on day 1 of each 14-day cycle, for six cycles after surgery **S**
- Fluorouracil 50 mg/mL injection, 3670 mg (2400 mg/m2) by continuous infusion over 46 hours from day 1 of each 14-day cycle, for six cycles after surgery **S**
- Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle after surgery **S**
- Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy after surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 84 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 52.4 kg; BMI 19.7 kg/m². All vital signs are synthetic.

PHQ-9: 5. All results are synthetic.

## Immunizations given today

- Influenza vaccine, this season (inactivated) **S**
- COVID-19 mRNA vaccine, this season's formula **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 52.4 kg, BMI 19.7; blood pressure 106/66 |
| Head, eyes, ears, nose, and throat | No mouth sores; no scleral icterus |
| Neck | No lymph nodes; thyroid normal |
| Breasts | Examined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Healed upper midline and right subcostal incision; soft, non-tender; no mass, no fluid |
| Skin | Port site clean; no rash or bruising |
| Feet | Monofilament sensation normal; pulses present; no lesions |
| Neurological | Light touch slightly reduced at the fingertips; vibration and reflexes normal; steady gait |
| Psychiatric | Thoughtful, wry and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated for a woman of 33 in treatment for pancreatic cancer. Cervical screening is due (last test four years ago, normal); she prefers to have it after chemotherapy ends, which is reasonable. Influenza and COVID-19 vaccines given today, between cycles; no live vaccines during chemotherapy. Hepatitis B surface antibody was negative before chemotherapy, so hepatitis B vaccination is due after chemotherapy, when the response will be better. Contraception was discussed again: estrogen-containing methods are not advised because of her clot risk; condoms for now, and a copper or levonorgestrel IUD if she wants one later. **S**
   - Influenza and COVID-19 vaccines given today.
   - Cervical screening (HPV test) after chemotherapy ends.
   - Hepatitis B vaccine series after chemotherapy.
   - Lipid panel with the next routine blood tests.
   - Next preventive visit in one year.
2. **Pancreatic head adenocarcinoma after neoadjuvant chemotherapy and pancreaticoduodenectomy (ypT2N1, R0), on chemotherapy after surgery** (C25.0). First cycle of fluorouracil, leucovorin and irinotecan tolerated well. Surveillance after treatment will be with history, examination, CA 19-9 and CT every three to six months for two years. **S**
   - Cycle 2 in five days.
   - Continue apixaban 2.5 mg twice daily during chemotherapy.
3. **Diabetes due to pancreatic disease, on insulin** (E08.9). Fasting glucose 110 to 140 mg/dL with no low readings; the dilated eye examination last week was normal. **S**
   - Continue insulin glargine 10 units at night.
   - A1c in December.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 106/66 mmHg |
| Depression screening | Completed today | PHQ-9 score 5; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | No alcohol since diagnosis |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Cervical cancer screening | Due | Due (last test four years ago, normal); HPV test planned after chemotherapy ends, at her choice |
| Breast cancer screening | Not indicated | Screening mammography starts at 40; no family history of breast or ovarian cancer; germline panel negative |
| Colorectal cancer screening | Not indicated | Starts at 45; germline panel negative for Lynch syndrome genes |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before chemotherapy; hepatitis B surface antibody negative |
| Diabetes care: A1c, eye and foot examination, urine albumin | Up to date | A1c 7.0% in August; dilated eye examination last week normal; foot examination today normal; urine albumin-to-creatinine ratio normal at the visit after surgery |
| Lipid screening | Due | Recommended for adults with diabetes; with the next blood tests |
| Influenza vaccine | Completed today | Inactivated vaccine given between cycles |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine given |
| Pneumococcal vaccine | Up to date | PCV20 before chemotherapy |
| Recombinant zoster vaccine | Up to date | Two doses, before and during chemotherapy, for an adult on immunosuppressive treatment |
| Hepatitis B vaccine | Due | Surface antibody negative; series after chemotherapy ends |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap four years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune from childhood doses; live vaccines are avoided during chemotherapy |
| Contraception counseling | Completed today | No estrogen because of clot risk; condoms for now; IUD offered for later |
| Dental examination | Due | Cleaning between cycles when counts are recovered |

## Advance care planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, building on her conversations with the palliative care team. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care proxy form. She said that she wants to be told everything about her illness directly and in plain words, never through someone else; that she wants all treatment that has a real chance of controlling the cancer, as long as she can think clearly and write; and that if the cancer returns and can no longer be controlled, she would want care focused on comfort and on time at her desk and with her friends, at home if possible, rather than intensive care. She asked that her pain be treated fully even if it makes her sleepier near the end. To be revisited at each change in her health and at least yearly. **S**

## Guideline basis

- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Cycle 2 in five days. Cervical screening and the hepatitis B vaccine series after chemotherapy. Next preventive visit in one year. **S**

